$2.4 Billion Actos Bladder Cancer Settlement Explained

September 28, 2015 - Beasley Allen principal Frank Woodson discusses the recent $2.4 billion Actos settlement on Ringler Radio. Read More

$2.4 billion settlement agreement reached in Actos bladder cancer litigation

April 29, 2015 - Takeda Pharmaceutical Co. has agreed to a $2.4 billion settlement to resolve bladder cancer claims tied to its Type 2 diabetes drug Actos. The settlement will compensate an anticipated... Read More

Actos verdict illustrates companies that co-promote drugs can be held liable for injuries, failure to warn

September 4, 2014 - A federal judge’s decision not to overturn a jury’s $9 billion verdict against Takeda Pharmaceutical Co. and Eli Lilly for withholding bladder cancer risks from doctors and patients... Read More

Actos and its link to bladder cancer discussed by Beasley Allen attorney Andy Birchfield

May 20, 2014 - Actos, manufactured by Takeda Pharmaceuticals, was issued a warning by the FDA saying people who have been taking the drug for a year or longer have an increased risk of developing bladder... Read More

Actos, TVM and Zohydro litigation discussed by Andy Birchfield and Leigh O’Dell on Ringler Radio

May 19, 2014 - Beasley Allen attorneys Andy Birchfield and Leigh O'Dell discuss their progress on litigation involving Actos, Transvaginal Mesh and Zohydro. Read More

Federal jury orders drug makers Takeda, Eli Lilly to pay $9 billion for Actos cancer risk

April 8, 2014 - Jurors found Takeda Pharmaceutical Co. and Eli Lilly & Co. liable for a combined $9 billion in punitive damages after finding the drug makers hid cancer risks associated with Actos... Read More

Type 2 diabetes drugs may increase risk of pancreatic cancer

August 12, 2013 - A commonly prescribed class of Type 2 diabetes drugs known as incretin mimetics may put users at risk for developing pancreatic cancer, according to new research published in the British... Read More


June 30, 2011 - Actos (pioglitazone), manufactured by Takeda Pharmaceuticals and distributed by Eli Lilly and Company, has been under FDA review since September 2010. In June 2011, the FDA issued a warning... Read More

Diabetes drug Actos pulled from French, German markets due to cancer link

June 10, 2011 - Drug regulators in France and Germany have suspended the use of the diabetes drug pioglitazone – found in brand name drug Actos, manufactured by Takeda - in light of a recent study... Read More

back to top